Abstract: Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.

Abstract: Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/ or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.

Abstract: At least one chemical entity chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof is described herein. Pharmaceutical compositions comprising at least one chemical entity of the invention, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.

Abstract: Certain imidazopyrazines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.

Abstract: Methods of inhibiting BTK activity by inhibiting phosphorylation of Y551 of BTK, methods of treating patients by inhibiting BTK activity by inhibiting phosphorylation of Y551 of BTK, chemical entities that bind to BTK and inhibited complexes are provided.

Abstract: Certain imidazopyrazines and pharmaceutical compositions thereof are provided herein. Methods of treating patients suffering from certain diseases and disorders responsive to the inhibition of Syk activity, which comprises administering to such patients an amount of at least one chemical entity effective to reduce signs or symptoms of the disease or disorder are provided. Also provided are methods for determining the presence or absence of Syk kinase in a sample.

Abstract: Analysis may be made of the amount that a load on a machine impacts the machine's performance. Performance counters on the machine record raw statistical data, such as a given resource's current utilization. The values of these counters may be captured. A n-bin histogram may be created that shows how many of the captured performance counter values occur within various ranges, such as 0-10% utilization, 10-20%, etc. A weight may be assigned to each bin. A weighted sum of the bins may be calculated by multiplying the number of occurrences in each bin by the bin's weight, and adding the products together. The weights may be chosen to reflect the relative amounts that particular performance counter values impact the overall performance of a machine. Thus, a metric that represents performance impact may be calculated based on the weighted sum.

Abstract: Compounds of Formula I that inhibit Btk are described herein. Pharmaceutical compositions comprising at least one compound of Formula I, together with at least one pharmaceutically acceptable vehicle chosen from carriers, adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.

Abstract: At least one chemical entity chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, prodrugs, and mixtures thereof is described herein. Pharmaceutical compositions comprising at least one chemical entity of the invention, together with at least one pharmaceutically acceptable vehicle chosen from carriers adjuvants, and excipients, are described. Methods of treating patients suffering from certain diseases responsive to inhibition of Btk activity and/or B-cell activity are described. Methods for determining the presence of Btk in a sample are described.

Abstract: A method of making a lumbricus powder wherein there is provided a quantity of worms which are cleaned and then masticated. The masticated worms are then hydrolyzed, this being accomplished by immersing the masticated worms in an enzyme ingredient. Then the product is freeze dried to make a lumbricus powder.

Abstract: A flow modulation device is provided for restricting fluid flow exhausted from a first, actuator-sided conduit toward a second, reservoir-sided conduit to an acceptable rate in the event of sudden pressure drop within the second conduit.

Abstract: This invention is a burn remedial composition which is produced by mixing powder of the high heated abalone shells with sesame oil extracted from sesame, and its production method wherein it is characteristic that the grinding process of abalone shells heated at a temperature higher than 3000.degree. C. and the mixing process of the ground abalone shell powder and sesame oil are not performed in a stone or metallic vessel, but in a wooden vessel. A pharmaceutical additive can be added to aid the formation of a pharmaceutical type of burn remedial composition. When the burn remedial composition of the invention is applied to every degree of heat burn and fire burn for which there are few curing agents, especially to severe burns, the analgesic and antiphlogistic effects happen at that moment, the toxic materials in the injured region are eliminated within 24 hours and the injury is completely cured within 3-5 days.

Abstract: An automatic tracking device which reproduces the biggest and clearest FM video signals onto a screen utilizes the concept that the width of the video heads are to be formed larger than the track of the video tape. The size of the video signals reproduced from these video heads are compared. From this comparison the automatic tracking device controls the video heads or tape speed to cause the video signal to be the same size without requiring a separate control track. This controlling of the video signals allows the biggest FM video signals to appear on a screen having substantially no noise.